价格

GLAXOSMITHKLINE AUSTRALIA PTY LTD

LEVEL 4 436 JOHNSTON STREET, Abbotsford, Victoria, 澳大利亚

别名:

diversified health systems

概览

试验阶段分布

阶段

试验数

占比

3 期

50.0%

4 期

50.0%

试验状态分布

进行中（未招募）

100.0%

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

TGA

Therapeutic Goods Administration

214

药物批准

NPRA

National Pharmaceutical Regulatory Agency

药物批准

近期批准

PANADOL Mini Caps 500 mg

OMJJARA momelotinib (as dihydrochloride monohydrate) 200 mg film-coated tablet bottle (442232)

TGA

2024-12-18

OMJJARA momelotinib (as dihydrochloride monohydrate) 100 mg film-coated tablet bottle (442230)

TGA

2024-12-18

OMJJARA momelotinib (as dihydrochloride monohydrate) 200 mg film-coated tablet bottle (442232)

TGA

2024-12-18

OMJJARA momelotinib (as dihydrochloride monohydrate) 100 mg film-coated tablet bottle (442230)

TGA

2024-12-18

OMJJARA momelotinib (as dihydrochloride monohydrate) 150 mg film-coated tablet bottle (442231)

TGA

2024-12-18

OMJJARA momelotinib (as dihydrochloride monohydrate) 150 mg film-coated tablet bottle (442231)

TGA

2024-12-18

AREXVY Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine 120 micrograms powder vial and suspension vial suspension for injection (400657)

TGA

2024-01-14

AREXVY Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine 120 micrograms powder vial and suspension vial suspension for injection (400657)

TGA

2024-01-14

资讯

暂无资讯文章

返回机构列表

GLAXOSMITHKLINE AUSTRALIA PTY LTD

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（2）

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study in Patients With HER2/ErbB2 Positive Primary Breast Cancer.

药物批准

按机构分类的批准

近期批准

资讯